NCT01093885 - Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

July 31, 2016

Study Completion Date

July 31, 2016

Conditions

Systemic SclerosisScleroderma

Interventions

DRUG

Ambrisentan

"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin~Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."

Trial Locations (1)

19104

University of Pennsylvania Health System, Philadelphia